- Home
- KZR vs CLGN Comparison
KZR vs CLGN Comparison
Compare KZR & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- CLGN
- Stock Information
- Founded
- KZR 2015
- CLGN 2004
- Country
- KZR United States
- CLGN Israel
- Employees
- KZR N/A
- CLGN N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- KZR Health Care
- CLGN Health Care
- Exchange
- KZR Nasdaq
- CLGN Nasdaq
- Market Cap
- KZR 29.7M
- CLGN 33.8M
- IPO Year
- KZR 2018
- CLGN N/A
- Fundamental
- Price
- KZR $3.88
- CLGN $2.64
- Analyst Decision
- KZR Hold
- CLGN Strong Buy
- Analyst Count
- KZR 2
- CLGN 2
- Target Price
- KZR $9.00
- CLGN $11.50
- AVG Volume (30 Days)
- KZR 34.0K
- CLGN 46.0K
- Earning Date
- KZR 08-13-2025
- CLGN 08-20-2025
- Dividend Yield
- KZR N/A
- CLGN N/A
- EPS Growth
- KZR N/A
- CLGN N/A
- EPS
- KZR N/A
- CLGN N/A
- Revenue
- KZR N/A
- CLGN $2,402,000.00
- Revenue This Year
- KZR N/A
- CLGN $1,999.42
- Revenue Next Year
- KZR N/A
- CLGN $69.81
- P/E Ratio
- KZR N/A
- CLGN N/A
- Revenue Growth
- KZR N/A
- CLGN 248.62
- 52 Week Low
- KZR $3.62
- CLGN $1.31
- 52 Week High
- KZR $9.18
- CLGN $5.45
- Technical
- Relative Strength Index (RSI)
- KZR 39.10
- CLGN 53.34
- Support Level
- KZR $3.84
- CLGN $1.87
- Resistance Level
- KZR $4.10
- CLGN $2.97
- Average True Range (ATR)
- KZR 0.14
- CLGN 0.31
- MACD
- KZR 0.01
- CLGN -0.02
- Stochastic Oscillator
- KZR 13.16
- CLGN 60.63
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.